Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
CDK6 Gene Editing 
CDK6 (cyclin-dependent protein 6) is a member of the cyclin-dependent kinase family, a serine/threonine protein kinase family involved in cell cycle, transcription, and other biological processes such as translation, neurogenesis, and apoptosis. CDK6 is a catalytic subunit of the CDK6-cyclin D complex that is involved in the G1 to S cell cycle progression and negatively regulates cell differentiation. Its activity first appeared in the mid-G1 phase to phosphorylate the tumor suppressor protein retinoblastoma (Rb) (Figure 1), thereby regulating its activity. In addition, the CDK4/6 cyclin D complex phosphorylates transcription factor, such as FOXM1. CDK6 has also been shown to phosphorylate the cancer factor kappa-B (NF-kB). CDK6 is required for certain tumor cells to proliferate, and the expression of CDK6 is up-regulated in several types of cancer. Therefore, CDK6 is expected to be a potential target for anticancer treatment.
Figure 1: Schematic representation of the function and regulation of CDK6
Despite the high level of homology between CDK4 and CDK6 (~70%), there are more and more lists of different functions reported for CDK6, including the ability to regulate specific differentiated cell type, like murine erythroleukemia, primary mouse astrocytes, osteoblasts and osteoclasts, thymic cells, neurons, cardiac cells and hematopoietic cells. Due to its unique function of cell-type specificity and development, CDK6 is a pharmacological target for various cancer types and it is necessary to find a CDK6 inhibitor with high selectivity.
CDK6 Gene Editing Service
CRISPR/Cas9 PlatformCB, one of the global leading biotechnological companies, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to support your genetic research. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we help you effectively control target genes knockout/knockin/point mutation in cells or animals via CRISPR/Cas9 technology.
- CDK6 Gene Editing Cell Line Generation
Our professional scientists have successfully implemented CDK6 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we will offer you full-length custom CDK6 gene editing service from strategy design to final stable cells. Our CDK6 gene editing cell line generation services include:
➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of CDK6 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report
Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.
- Alternative cell lines
➢ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
➢ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87 etc.)
➢ Stem Cells (iPSC)
➢ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)
- CDK6 Gene Editing Animal Model Generation
CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide a one-stop-shop CDK6 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our CDK6 gene editing animal model generation services include:
➢ CDK6 gene conventional knockout animals
➢ CDK6 gene conditional knockout animals
➢ CDK6 point mutation animals
➢ CDK6 knockin animals
Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.
CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services to accelerate the achievement of your research goals. We provide you with one-stop custom service to meet your special requirements with excellent quality management and quality assurance capacity. There is no doubt that CRISPR/Cas9 PlatformCB will be your best partner to support your research.
Related Products at CRISPR/Cas9 PlatformCB
| CATALOG NO. | PRODUCT NAME | INQUIRY |
| CLKO-1388 | CDK6 KO Cell Lysate-HeLa | Inquiry |
| CSC-RT1541 | Human CDK6 Knockout Cell Line-HeLa | Inquiry |
References
- Solomon Tadesse. et al. Targeting CDK6 in cancer: State of the art and new insights. Cell Cycle. 2015; 14(20):3220–3230.
- Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014; 15:122.
- Malumbres M. et al. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9:153-66.
- A-S Tigan. et al. CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene. 2016; 35:3083–3091.
- Charles J. et al. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discovery. 2016; 6(4):353-367.
- Ruth Scheicher. et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015; 125:90-101.